Acceleron's earnings call highlighted significant progress in regulatory filings for luspatercept, with positive feedback from both the FDA and EMA.  The company also reported encouraging Phase 2 trial results for ACE-083 and sotatercept, with anticipated top-line data releases in the coming months.  These positive developments suggest a strong likelihood for a positive impact on the stock price in the short term.
[2]
